Canada markets open in 40 minutes
  • S&P/TSX

    20,157.65
    +19.30 (+0.10%)
     
  • S&P 500

    4,255.15
    +7.71 (+0.18%)
     
  • DOW

    34,393.75
    -85.85 (-0.25%)
     
  • CAD/USD

    0.8203
    -0.0031 (-0.38%)
     
  • CRUDE OIL

    71.67
    +0.79 (+1.11%)
     
  • BTC-CAD

    48,764.71
    +317.43 (+0.66%)
     
  • CMC Crypto 200

    1,000.01
    +31.17 (+3.22%)
     
  • GOLD FUTURES

    1,868.10
    +2.20 (+0.12%)
     
  • RUSSELL 2000

    2,326.15
    -9.66 (-0.41%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,127.75
    +3.00 (+0.02%)
     
  • VOLATILITY

    16.57
    +0.92 (+5.88%)
     
  • FTSE

    7,185.04
    +38.36 (+0.54%)
     
  • NIKKEI 225

    29,441.30
    +279.50 (+0.96%)
     
  • CAD/EUR

    0.6772
    -0.0021 (-0.31%)
     

Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Berwyn, Pennsylvania--(Newsfile Corp. - May 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that management will participate at the Benzinga Global Small Cap Conference taking place online May 13-14, 2021.

Annovis Bio CEO Maria Maccecchini, Ph.D. will deliver a corporate presentation at 3:10 p.m. ET on May 13, 2021.

Investors can request a one-on-one meeting with Dr. Maccecchini and Annovis Bio CFO Jeff McGroarty using the networking feature within the virtual conference platform.

To register for the conference, visit: https://www.benzinga.com/events/small-cap/global/

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.

Forward-Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

SOURCE: Annovis Bio, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83598